Evidence mapPaperPMID 41235241Full record

ReviewFrontiers in immunology2025

Therapeutic challenges in central nervous system viral infections: advancing mesenchymal stem cell-based strategies for treating neuroinflammation and promoting tissue repair.

Javier Carbone-Schellman, Javiera Fontecilla-Escobar, Nicolás Sales-Salinas, William F Chaparro-Pico, Alfredo Molina-Berríos, María Celeste Ruete, Pablo A González, Mayra A Machuca, Ma Cecilia Opazo, Marcelo E Ezquer and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Javier Carbone-Schellman *Centro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana - Universidad del Desarrollo, Santiago, Chile.
Javiera Fontecilla-Escobar *Centro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana - Universidad del Desarrollo, Santiago, Chile.
Nicolás Sales-SalinasCentro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana - Universidad del Desarrollo, Santiago, Chile.
William F Chaparro-PicoEscuela de Microbiología, Universidad Industrial de Santander, Bucaramanga, Colombia.
Alfredo Molina-BerríosInstitute for Research in Dental Sciences, Faculty of Dentistry, Universidad de Chile, Santiago, Chile.
María Celeste RueteLaboratorio de Cannabinoides y Biología Espermática, Instituto de Histología y Embriología de Mendoza, Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad Nacional de Cuyo, Mendoza, Argentina.
Pablo A GonzálezMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Mayra A MachucaEscuela de Microbiología, Universidad Industrial de Santander, Bucaramanga, Colombia.
Ma Cecilia OpazoInstituto de Ciencias Naturales, Facultad de Medicina Veterinaria y Agronomía, Universidad de Las Américas, Santiago, Chile.
Marcelo E EzquerCentro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana - Universidad del Desarrollo, Santiago, Chile.
Luisa F DuarteCentro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana - Universidad del Desarrollo, Santiago, Chile.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although significant progress has been made in medicine and antimicrobial research, viral infections continue to pose a critical global health challenge, particularly when they involve the central nervous system (CNS). Despite advances in vaccines, antiviral agents, and small molecule therapeutics, current strategies remain insufficient to address the complex consequences of many CNS infections fully. Notably, many viruses are neurotropic and can invade the CNS, triggering infectious neuroinflammation that often lead to chronic neurological disorders and lasting morbidity. Current therapeutic approaches are largely ineffective in preventing or reversing this long-term neurological damage, underscoring the urgent need for innovative prophylactic and therapeutic interventions. Mesenchymal stem cells (MSCs) have emerged as a promising strategy to counteract chronic neuroinflammation and promote tissue repair following viral CNS infections. This review provides a comprehensive overview of CNS viral infection and neuroinflammation, including epidemiology and pathophysiology, and critically examines the limitations of existing treatments, particularly their inability to mitigate persistent neurological sequelae. Furthermore, we summarize recent preclinical and clinical studies investigating the use of MSCs in the context of CNS viral infections, highlighting their immunomodulatory and neuroprotective mechanisms, and discuss the challenges and future directions for MSC-based therapies in clinical settings.

Indexed as

Central Nervous System Viral DiseasesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationNeuroinflammatory DiseasesAnimalsHumanscentral nervous system (CNS)extracellular vesicle (EV)mesenchymal stem cellsneuroinflammationneurological and neurodegenerative diseasespersistent infectionssecretomevirus

Identifiers

PMID41235241
PMCPMC12605362

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.